This HTML5 document contains 106 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/drugbank/
n26http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n31http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/national-drug-code-directory/
n17http://linked.opendata.cz/resource/drugbank/mixture/
n25http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/chebi/
n28http://www.rxlist.com/cgi/generic/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n30http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/bindingdb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/pubchem-compound/
n20http://linked.opendata.cz/ontology/sukl/drug/
n21http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01077/identifier/pubchem-substance/

Statements

Subject Item
n2:DB01077
rdf:type
n3:Drug
n3:description
A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. [PubChem]
n3:dosage
n29:271B61B3-363D-11E5-9242-09173F13E4C5 n29:271B61B2-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.
n3:indication
For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
owl:sameAs
n23:DB01077 n25:DB01077
dcterms:title
Etidronic acid
adms:identifier
n7:0378-3286-91 n8:PA449548 n9:C07736 n10:D00314 n11:3305 n12:46507694 n13:50115102 n14:DB01077 n15:4907 n16:3189 n18:Etidronic_acid
n3:mechanismOfAction
Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid does not interfere with bone mineralization. In malignancy-related hypercalcemia, etidronic acid decreases serum calcium by inhibiting tumour-induced bone resorption and reducing calcium flow from the resorbing bone into the blood. Etidronic acid also reduces morbidity of osteolytic bone metastases by inhibiting tumour-induced bone resorption. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.
n3:packager
n24:271B61A8-363D-11E5-9242-09173F13E4C5 n24:271B61AD-363D-11E5-9242-09173F13E4C5 n24:271B61AB-363D-11E5-9242-09173F13E4C5 n24:271B61AC-363D-11E5-9242-09173F13E4C5 n24:271B61A9-363D-11E5-9242-09173F13E4C5 n24:271B61AA-363D-11E5-9242-09173F13E4C5 n24:271B61A4-363D-11E5-9242-09173F13E4C5 n24:271B61A5-363D-11E5-9242-09173F13E4C5 n24:271B61A6-363D-11E5-9242-09173F13E4C5 n24:271B61A7-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Etidronate disodium is not metabolized. Within 24 hours, approximately half the absorbed dose is excreted in urine; the remainder is distributed to bone compartments from which it is slowly eliminated. Unabsorbed drug is excreted intact in the feces.
n3:synonym
HEDP (1-Hydroxyethylidene)diphosphonic acid Acido etidronico Acide etidronique 1-Hydroxyethanediphosphonic acid (Hydroxyethylidene)diphosphonic acid 1-Hydroxy-1,1-diphosphonoethane Etidronsäure (1-Hydroxyethylene)diphosphonic acid Ethane-1-hydroxy-1,1-bisphosphonic acid 1-Hydroxyethylidene-1,1-diphosphonic acid Hydroxyethanediphosphonic acid 1-hydroxyethane 1,1-diphosphonic acid Etidronate 1-Hydroxyethane-1,1-diphosphonate 1-Hydroxyethylidene-1,1-bisphosphonate 1-Hydroxyethane-1,1-bisphosphonic acid (1-Hydroxyethylidene)bisphosphonic acid Ethane-1-hydroxy-1,1-diphosphonic acid (1-Hydroxyethylidene)bis(phosphonic acid) EHDP Etidronsaeure 1,1,1-Ethanetriol diphosphonate Ethane-1-hydroxy-1,1-diphosphonate Acetodiphosphonic acid Acidum etidronicum 1-Hydroxyethane-1,1-diphosphonic acid Oxyethylidenediphosphonic acid
n3:toxicity
Clinical experience with acute etidronic acid overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.
n20:hasAHFSCode
n26:92-00-00
n3:foodInteraction
Avoid aluminium, calcium, iron and magnesium within 2 hours of taking medication. Take on an empty stomach with a full glass of water.
n3:mixture
n17:271B61A3-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Rogovin, L.,Brawn, D.P. and Kalberg, AN.; US. Patent 3,400,147; September 3,1968; assigned to The Procter & Gamble Co.
n30:hasConcept
n31:M0020098
foaf:page
n28:didronel.htm
n3:IUPAC-Name
n4:271B61B8-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B61BE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B61BD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B61BA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B61BB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B61BC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61B6-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B61CE-363D-11E5-9242-09173F13E4C5 n4:271B61B7-363D-11E5-9242-09173F13E4C5 n4:271B61B4-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B61B5-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:M05BA01
n3:H-Bond-Acceptor-Count
n4:271B61C4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B61C5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B61BF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B61C0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B61C2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B61C1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B61C3-363D-11E5-9242-09173F13E4C5
n3:absorption
The amount of drug absorbed after an oral dose is approximately 3%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7414-83-7
n3:category
n3:containedIn
n5:271B61AE-363D-11E5-9242-09173F13E4C5 n5:271B61B1-363D-11E5-9242-09173F13E4C5 n5:271B61AF-363D-11E5-9242-09173F13E4C5 n5:271B61B0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B61CA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B61CC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B61CD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B61C9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B61C8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B61CB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B61B9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B61C6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B61C7-363D-11E5-9242-09173F13E4C5